Evidence map›Paper›PMID 37664289›Full record

ArticleCureus2023

Breast Cancer Management Timelines in a Tertiary Care Center During the COVID-19 Pandemic, Makkah City, Saudi Arabia: A Retrospective Study.

Abdulrahman H Alhassani, Abdulmohsen S Alqurashi, Turki H Alhassani, Sarah M Fageeh, Mohammad I Almatrafi, Emad K Alsharif, Abdulaziz M Alzahrani, Roaa A Attieh

Abstract read
In one paragraph

Article in Cureus, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Abdulrahman H AlhassaniGeneral Surgery, Makkah Healthcare Cluster, Makkah, SAU.
Abdulmohsen S AlqurashiFaculty of Medicine, Umm Al-Qura University, Makkah, SAU.
Turki H AlhassaniFaculty of Medicine, Umm Al-Qura University, Makkah, SAU.
Sarah M FageehFaculty of Medicine, Umm Al-Qura University, Makkah, SAU.
Mohammad I AlmatrafiFaculty of Medicine, Umm Al-Qura University, Makkah, SAU.
Emad K AlsharifDivision of Breast and Endocrine Surgery, Specialized Surgical Unit, King Abdullah Medical City, Makkah, SAU.
Abdulaziz M AlzahraniDivision of Breast and Endocrine Surgery, Specialized Surgical Unit, King Abdullah Medical City, Makkah, SAU.
Roaa A AttiehDivision of Breast and Endocrine Surgery, Specialized Surgical Unit, King Abdullah Medical City, Makkah, SAU.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundBreast cancer (BC) is a prevalent form of cancer and a leading cause of death among women worldwide. In Saudi Arabia, it accounted for 31.8% among females of all new cancer cases reported in 2018. Following the declaration of COVID-19 as a global pandemic, there was a complete redistribution of healthcare resources to face this crisis, which caused a significant delay in the management of various diseases, including BC. There is currently a lack of research in our region on the facility time interval in BC management. Therefore, this study aimed to fill this gap by determining the timelines of diagnosis, management, and factors influencing the delay.

methodsThis observational retrospective study included all female patients diagnosed with BC at or referred to King Abdullah Medical City (KAMC) in Makkah, Saudi Arabia, between January 2020 and August 2021. The data for this study were obtained from a centralized electronic chart review of all included patients at the KAMC center.

resultsA total of 76 patients were included in the study, with a mean age of 50 ± 11 years. In terms of the disease management duration, 20 patients (26.3%) completed their management within 30 days, 28 patients (36.8%) had a management duration between 31 and 60 days, and the management duration of 28 patients (36.8%) exceeded 60 days. Patient deposition showed a significant association with delay (p = 0.033). A higher incidence of delays at the initiation of treatment was observed in patients who failed to attend appointments (p < 0.001). Among patients who skipped two or more appointments, 12 individuals (80%) experienced a delay of more than 60 days. Moreover, appointment cancellation was associated with delayed treatment initiation (p = 0.03). Patients' age and comorbidity showed no significant association (p = 0.49, p = 0.24, respectively).

conclusionOur findings highlight the significant impact of patient deposition and canceled or skipped appointments on delayed initiation of therapy for BC patients. Further research should be conducted to evaluate the impact of COVID-19 on other malignancies.

Indexed as

breast neoplasmscovid-19patient depositionskipped appointmentstimelines of management

Identifiers

PMID37664289
PMCPMC10474793

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.